Clinical trials: Coronary Vessel
Coronary Artery Disease, Pain
Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy
This study was to determine whether ranolazine was effective in the treatment of neuropathic pain in patients with coronary artery disease.
- Conditions
- Coronary Artery Disease, Pain, Peripheral Nervous System Diseases, Polyneuropathy
- Trial name
- NCT00832572
- Testing
- Ranolazine
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Gilead Sciences
Hypercholesterolemia
Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia
Study of efficacy, safety, tolerability and quality of life of inclisiran (KJX839) vs placebo, on top of ongoing individually optimized lipid-lowering therapy, in participants with hypercholesterolemia
- Trial name
- V-DIFFERENCE (NCT05192941)
- Testing
- Inclisiran Sodium
- Where
- 136 sites in Bulgaria, Czechia and 6 more
- Volunteers
- 1,770 people
- Sponsor
- Novartis Pharmaceuticals
Myocardial Infarction
Determining the Optimal Cut-off Point of PEA by Corsens Device for Discriminating Between MI and Non-MI Subjects
Acute Myocardial Infarction (MI) is still the leading cause of death in the western world. Early warning (chest pain) signs of an acute MI are often misinterpreted and disregarded.
- Trial name
- NCT02723851
- Testing
- Corsens
- Volunteers
- 76 people
- Sponsor
- Corsens Medical LTD
Acute Coronary Syndrome
A NIS Registry of the Prospective Structured Care In Acute Coronary Syndrome
The purpose of the study is to analyse patient's acceptance and willingness to participate in a Structured Care Program (SCP) over 12 months following hospital discharge after Acute Coronary Syndrome (ACS) index event.
- Trial name
- ProAcor (NCT01490645)
- Where
- 45 sites in Germany
- Volunteers
- 1,006 people
- Sponsor
- AstraZeneca
Coronary Stenosis
Thin Strut Sirolimus-eluting Stent in All Comers Population vs Everolimus-eluting Stent
The primary objective of this study is to compare the performance of SUPRAFLEX to that of XIENCE in an all-comers patient population with symptomatic ischemic heart disease.
- Trial name
- TALENT (NCT02870140)
- Testing
- SUPRAFLEX, XIENCE
- Where
- 23 sites in Bulgaria, Hungary and 5 more
- Volunteers
- 1,435 people
- Sponsor
- ECRI bv
Coronary Artery Disease
A Phase I Study to Evaluate BFPET as a Potential Myocardial Perfusion Imaging(MPI) Agent for PET
Safety and dosimetry of BFPET™ will be evaluated in healthy volunteers and Coronary Artery Disease (CAD) patients , male or female and of age ranging between 20-80 years old.
- Trial name
- NCT00733460
- Testing
- BFPET
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Fluoropharma, Inc.
Peripheral Vascular Disease, Cardiovascular Disease
RISE: A Clinical Evaluation of the StarClose™ Vascular Closure System
To evaluate early ambulation in patients who receive the StarClose™ VCS post-percutaneous diagnostic procedure.
- Trial name
- NCT00736086
- Testing
- Vessel Closure (StarClose™)
- Where
- 11 sites in United States
- Volunteers
- 165 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
A Double-Blind Study of E5555 in Japanese Subjects With Coronary Artery Disease
The purpose of this study is to assess the safety and tolerability of E5555 in Japanese subjects with coronary artery disease.
- Trial name
- NCT00540670
- Testing
- E5555 50 mg, E5555 100 mg, E5555 200 mg
- Where
- 25 sites in Japan
- Volunteers
- 240 people
- Sponsor
- Eisai Co., Ltd.
Coronary Artery Disease (CAD)
Comparison of Effect & Safety of Clopidogrel Napadisilate With Clopidogrel Bisulfate in Coronary Artery Disease Patients
The aim of this study is to demonstrate that the combination therapy of aspirin and clopidogrel napadisilate is not inferior to that of aspirin and clopidogrel bisulfate with respect to its effectiveness in inhibiting platelet…
- Trial name
- NCT01830491
- Testing
- Clopidogrel, aspirin 100mg
- Volunteers
- 162 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Acute Coronary Syndrome
Canadian Ticagrelor Survey
This study is designed to evaluate the effectiveness of the current ticagrelor risk minimisation strategy in Canada through a prescriber knowledge and understanding (KAU) survey of selected important identified safety concerns…
- Trial name
- NCT01757483
- Where
- Canada
- Volunteers
- 244 people
- Sponsor
- AstraZeneca
Atrial Fibrillation, Stroke
WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation
This is a multi-center, prospective, randomized study, stratified by center, comparing the WATCHMAN device to long term warfarin therapy, demonstrating that the treatment arm is non-inferior to the control arm.
- Trial name
- NCT00129545
- Testing
- WATCHMAN Left Atrial Appendage Closure Technology, Warfarin
- Where
- 62 sites in United States, Czechia and 1 more
- Volunteers
- 800 people
- Sponsor
- Boston Scientific Corporation
Atrial Fibrillation
Real-world Comparative Effectiveness of Dabigatran Versus Vitamin K Antagonist
To obtain a better understanding on the comparative effectiveness of dabigatran versus Vitamin K antagonist (VKA) for stroke prevention in patients with Non-valvular atrial fibrillation (NVAF) in a real-life setting.
- Trial name
- DABI-F (NCT02687867)
- Testing
- Dabigatran (Pradaxa), Vitamin K antagonist
- Where
- United States
- Volunteers
- 56,039 people
- Sponsor
- Bayer
Stroke, Patent Foramen Ovale
AMPLATZER PFO Occluder Post Approval Study
The purpose of this single arm, multi-center study is to confirm the safety and effectiveness of the AMPLATZER™ PFO Occluder in the post Approval Setting.
- Trial name
- PFO PAS (NCT03309332)
- Testing
- AMPLATZER™ PFO Occluder
- Where
- 88 sites in United States, Canada and 5 more
- Volunteers
- 1,214 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
GUARD-AKI: Validation of AKI-Sapere in Cardiac Surgery Patients
Cardiac surgery associated acute kidney injury (CSA-AKI) has been recognized as the second most common cause of hospital acquired AKI.
- Trial name
- NCT03635606
- Where
- 3 sites in United States
- Volunteers
- 370 people
- Sponsor
- Sapere Bio
Diabetes Mellitus, Type 2
An International Survey of the Occurrence of Diseases That Affects the Heart and Blood Vessels Among People With Type 2 Diabetes
The purpose of the study is to register the occurrence of cardiovascular disease among type 2 diabetes (T2DM) patients across five selected countries in Europe. Participants will be asked to give information about their health.
- Trial name
- EU-CAPTURE (NCT03786406)
- Testing
- No treatment given
- Where
- 41 sites in Czechia, France and 1 more
- Volunteers
- 2,275 people
- Sponsor
- Novo Nordisk A/S
Myocardial Infarction
A Study of NP-011 in Healthy Volunteers
This is a Phase 1, randomised, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to evaluate the safety, tolerability, and pharmacokinetic of NP-011 in healthy volunteers.
- Trial name
- NCT05387499
- Testing
- NP-011 (Single Ascending Dose Phase), NP-011 (Multiple Ascending Dose Phase)
- Where
- Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Nexel Co., Ltd.
Coronary Atherosclerosis
Comparison of the Conor Sirolimus-eluting Coronary Stent to the Taxus Liberte Paclitaxel-eluting Coronary Stent in the Treatment of Coronary Artery Lesions
The purpose of this study is to evaluate the safety and effectiveness of the Conor Sirolimus-eluting Coronary Stent System in the treatment of coronary artery disease (a single atherosclerotic lesion) in native coronary arteries.
- Trial name
- NEVO RES-I (NCT00606333)
- Testing
- NEVO™ Sirolimus-eluting Coronary Stent System, Drug-eluting stent (TAXUS Liberte Paclitaxel-eluting Coronary Stent System)
- Where
- 2 sites in Brazil, New Zealand
- Volunteers
- 394 people
- Sponsor
- Cordis US Corp.
Atherosclerosis
SB-480848 In Subjects With Coronary Heart Disease
This trial of SB-480848 in approximately 920 subjects with Coronary Heart Disease (CHD) or CHD-risk equivalent will examine whether SB-480848 produces sustained inhibition of plasma Lp-PLA2 activity, explore the effects of…
- Trial name
- NCT00269048
- Testing
- SB-480848
- Where
- 119 sites in United States, Argentina and 14 more
- Volunteers
- 969 people
- Sponsor
- GlaxoSmithKline
Anemia, Diabetes
A Comparative Clinical Trial of the TensorTip, a Novel Non Invasive Device for Measurement Blood Parameters
1. Aim: The aim of the clinical trial is to study the accuracy of the TensorTip device compared with registered (FDA-approved) invasive and non-invasive devices. 2.
- Conditions
- Anemia, Diabetes, Heart Disease, High Blood Pressure
- Trial name
- NCT01196533
- Testing
- Non invasive peripheral blood monitoring
- Where
- United States
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Cnoga Medical Ltd.
Coronary Artery Stenosis
De Novo Pilot Study, Lutonix Catheter in Conjunction With Bare Metal Stenting for Treatment of Coronary De Novo Lesions
The study will enroll patients with angiographically significant coronary de novo lesions. Subjects will be randomized 1:1 and treated with a Lutonix catheter either before or after bare-metal stenting (BMS).
- Trial name
- NCT00934752
- Testing
- Lutonix Paclitaxel-Coated Balloon
- Where
- 3 sites in Netherlands
- Volunteers
- 24 people
- Sponsor
- C. R. Bard